Protalix BioTherapeutics Q4 GAAP EPS $(0.07) Misses $(0.03) Estimate, Sales $10.49M Beat $5.80M Estimate
Portfolio Pulse from Benzinga Newsdesk
Protalix BioTherapeutics (AMEX:PLX) reported Q4 GAAP EPS of $(0.07), missing estimates by 133.33%, but sales of $10.49M exceeded expectations by 80.79%, marking a 21.69% increase from last year.
March 14, 2024 | 10:56 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Protalix BioTherapeutics reported a Q4 GAAP EPS of $(0.07), missing estimates, but sales of $10.49M exceeded expectations, showing significant growth.
The miss on EPS could concern investors about profitability, but the substantial beat on sales and year-over-year growth may indicate strong demand for its products. The mixed results present a neutral short-term outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100